登录

SceneRay Completes ¥100M Series C Financing

作者: Mailman 2021-05-06 09:41
景昱医疗
http://www.sceneray.com
企业数据由 动脉橙 提供支持
创新型高科技医疗器械研发、生产商 | D+轮 | 运营中
中国-江苏
2022-02-16
融资金额:RMB¥3亿
红杉资本中国基金
查看

(VCBeat) Apr. 21, 2021 -- SceneRay Co., Ltd., a leading domestic medical device company focusing on the development and production of deep brain stimulation (DBS) system, announced the completion of a Series D funding round of over 100 million yuan, led by Yanchuang Capital, with participation from DYEE Capital, Tahoe Capital, Shanghai Yehao and others. China Renaissance acted as the exclusive financial adviser for this transaction.


The funds raised will be mainly used for the development and clinical trials for new indications of SceneRay's existing DBS products under development, and the marketing and commercialization of the listed product line. In the future, the company will continue to provide more overall solutions for clinical treatment and better benefit the vast number of Parkinson's disease patients in China.


Founded in 2009, SceneRay is an innovative high-tech medical device company integrating R&D, production, and sales of DBS systems. SceneRay has gathered excellent talents from Tsinghua University, Peking University, Jiaotong University, Fudan University and overseas returnees to build a professional R&D team. According to market changes, SceneRay continues to carry out technological innovation and product R&D. It has obtained more than 200 domestic patents and more than 10 international patents.


In the frontier field of neuroscience, SceneRay has made outstanding achievements by virtue of its core technology and independent R&D capabilities and will continue to deeply empower the industry reform with its leading technology in the future.


Since 2012, SceneRay cooperated with Professor Gao Guodong of Air Force Military Medical University to develop a drug-reducing brain-computer chip and a drug-reducing DBS system based on theoretical and technological innovations in addiction mechanisms, committed to solving the high relapse after drug addiction. A single-center detoxification clinical trial has been completed and breakthrough results have been achieved. This detoxification brain pacemaker is the world's first medical device with multi-targets combined regulation in the brain for drug addiction and treatment of mental illness. 


At present, SceneRay's detoxification DBS system is undergoing strict national standard (prospective, multi-center, double-blind, randomized controlled) national multi-center clinical trials, which has further verified its therapy.


>>>>

About Yanchuang Capital


Founded in June 2010, Yanchuang Capital is a high-tech investment and capital operation platform jointly initiated by alumni of Peking University and alumni enterprises engaged in venture capital investment and the transformation of university technological achievements under the advocacy and support of the Science and Technology Development Department of Peking University. 


At present, Yanchuang Capital has three business segments, namely equity investment, securities investment, listed company cooperation & merger and reorganization, with an AUM of more than 6 billion yuan.


>>>>

About DYEE Capital


DYEE Capital is a private equity & venture capital firm. Founded in June 2016, DYEE Capital focuses on modern services and investing in medical care, information services, consumption upgrading, and other fields.

相关赛道 其它耗材
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】聚禾生物完成近亿元A轮融资,海邦投资领投,探针资本担任独家财务顾问

【首发】儒翰基因完成数千万天使轮融资,加速固态纳米孔基因测序仪及生物大分子检测领域的产品研发

NowYon Medical Scores ¥100M in Series A and A+ Round of Financing

Ustar Raises ¥100M in A New Funding Round

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

GensKey Receives a ¥100 Million Stragetic Financing from CPE

2021-05-06
下一篇

个性化诊疗论坛:基因检测助力精准医疗,个性化诊疗迎来黄金时代

2021-05-06